(MedPAC) involves comparing costs with payment rates -an approach that does not identify services whose utilization is increasing because prices are set too high. Japan has taken a different approach in responding to high rates of utilization, by monitoring specific services whose use grows substantially, rather than lumping all physician procedures together. In the United States, line-item revisions could replace the SGR and guide revisions of the resource-based relative-value scale, DRGs, and Ambulatory Payment Classification rates.
One reason for the success of this policy in Japan is the country's system of setting rates for all payers. Unless other U.S. payers implemented the same approach as Medicare, Medicare beneficiaries could have problems with access to the services whose reimbursement rates were reduced. Although Japan's evaluation of volume in determining prices is instructive, the United States may want to develop its own approach to determining whether a volume increase is appropriate or inappropriate for a particular procedure.
Creating a high-performing health system entails challenges that are being addressed by other countries. Incorporation of international evidence-based policy initiatives might enhance U.S. costcontainment efforts. Germany's bundled payments and Japan's payment adjustments are two of the many options that are translatable and relevant to the U.S context. Nevertheless, we at the NIH share the concern that some of the best, most creative clinically trained scientists are shying away from research, and we want to work with the broader research community to help reverse this trend. The profound effect that clinically trained scientists have had on our understanding of basic human biology argues that we must sustain the flow of such scientists into research careers. To do so, we must surmount two barriers: an apparently decreasing interest by medical and dental students in establishing research careers and the increasing difficulty that research-oriented physicians and dentists face in pursuing their research interests full time without the distractions of clinical practice.
The NIH is addressing the former problem -getting students, Two NIH-trained physicianscientists, Joseph Goldstein and Michael Brown, both 1985 Nobel laureates, recently noted that the special environment at the NIH in the 1960s and 1970s -including the presence of a talented group of senior scientists and a dedication to supporting research to uncover basic principles of biology -provided ambitious physician-scientists with fertile ground for success. 4 The new NIH-Lasker program builds on this legacy.
This collaboration with the Lasker Foundation aims to attract a new generation of medical researchers to continue their training at the NIH for 5 years or longer; here, they will be able to take advantage of the NIH Clinical Center and our community of more than 1100 principal investigators and 6000 trainees. The hope is to expand the pool of talented clinically trained researchers at both academic institutions and the NIH by providing substantial and protected full-
The NIH has already begun recruiting for this program. We now have two researchers on our Bethesda campus, and we envision a steady state of at least 20 researchers at various stages in their careers benefiting from the proximity to our laboratory facilities, mentors, and role models The shortfall of new physicianresearchers is a national, if not global, concern, and its remedy requires a coherent and cooperative approach among biomedical research and teaching institutions. We hope that our actions will help to recreate the environment of the 1960s and 1970s that Goldstein and Brown describe, in which so many physician-scientists (many of whom came to the NIH as officers in the U.S. Public Health Service Commissioned Corps to fulfill their Selective Service obligation) were trained and developed scientific maturity and independence before pursuing research careers.
The best attraction to a clinical research career may be the promise to a physician of committed funding to conduct the clinically oriented or basic research of his or her choice. Goldstein and Brown argue that the best science done by physician-scientists occurs in an atmosphere that is not oriented to clinical outcomes but seeks only to elucidate basic biologic processes. 4 Jeffrey Flier, dean of the Faculty of Medicine at Harvard Medical School, notes that it's the confluence of talented individuals and "magical" research opportunities at the NIH that enables success. 5 The major contributions that clinically trained scientists have made to our understanding of human biology have come not from anything unique about their research skills, but rather from their perspective derived from clinical experience or training that enables them to define and pursue important problems in human biology, especially in a highly supportive research environment.
The NIH hopes to serve as a catalyst for a national effort to nurture clinician-scientists by providing such varied opportunities in an incubator-like environment, by demonstrating the value of investing in protected research time, and by inspiring partnerships and complementary clinically oriented research programs at major institutions.
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S
hortly after the shootings in Newtown, Connecticut, two of us received letters from our county sheriff in North Carolina asking whether one of our patients had medical or physical conditions that would preclude issuance of a permit to carry a concealed weapon. Uncomfortable with our limited knowledge about such permits and our expected role, and fearing that our participation could affect our relationships with patients, we began exploring the ethical, legal, and policy considerations regarding physician involvement in this process.
Although the U.S. Supreme Court recently held that the Second Amendment protects an individual's right to possess guns for traditionally lawful purposes, that right is subject to reasonable legislative limitations. Federal law, for example, prohibits gun sales to felons, persons found to abuse controlled substances, persons with a history of domestic violence, and persons deemed dangerously mentally ill. The Brady Law requires background checks for gun purchases from federally licensed dealers.
Although denying weapons to people with prior convictions seems relatively straightforward, it's more difficult to assess mental competence and current or future risk for violence. Even with drug testing, it's often difficult to detect clinically whether a person is abusing illegal substances, controlled prescription drugs, or alcohol. Waiting periods for gun purchases vary by state, and sales by private parties require no background checks or substance-abuse clearance.
Every U.S. state allows some persons to carry certain concealed weapons in public, after varied approval processes. States also vary on who, if anyone, has the authority to deny gun permits to individuals -some states prohibit denial if certain criteria are met; others allow law-enforcement agencies to deny permits regardless. The number of permit applications for concealed weap- 
